SINGAPORE — A two-drug HIV therapy that GlaxoSmithKline hopes can be delivered via a single pill is a candidate to enter China’s fast-track review process — making it a rare, and potentially lucrative, example of a cutting-edge therapy reaching emerging markets.
Both drugs in the combo therapy — Tivicay and Complera — are already approved and manufactured in China. The combination showed strong results in recent Phase III clinical trials, performing as well as three- and four-drug cocktails. GSK hopes the two-drug regimen will have fewer side effects for HIV patients.
